Acute Kidney Injury after Bone Marrow Transplantation in Patients with Lymphomas and Leukemias / Lesão Renal Aguda após Transplante de Medula Óssea em Pacientes com Linfomas e Leucemias Insuficiencia Renal Aguda tras / Trasplante de Médula Ósea en Pacientes con Linfomas y Leucemias

Introduction: Hematologic malignancies, including lymphomas and leukemias, may be treated with autologous or allogeneic bone marrow transplantation. However, these approaches can increase the risk of infection, sepsis, graft-versus-host disease, and nephrotoxicity, possibly resulting in acute kidney injury (AKI). Objective: To evaluate AKI in patients with lymphomas or leukemia submitted to bone marrow transplantation (BMT). Method: Retrospective, observational cohort study of cases from a database of 256 patients (53.9% males) hospitalized for BMT between 2012 and 2014 at a cancer hospital in São Paulo, Brazil. Of these, 79 were selected randomly for analysis. Demographic data, length of hospitalization, and associated morbidities were recorded. AKI was identified according to Kidney Diseases Improving Global Outcomes (KDIGO) criteria. Results: The most frequent diagnoses for the 79 cases were non-Hodgkin's lymphoma (30.4%), acute myeloid leukemia (26.6%), and Hodgkin's lymphoma (24.1%). The probability of 100 days-survival after BMT was 81%, and three years after BMT was 61%. In-hospital mortality was significantly higher among patients who presented AKI during hospitalization (p<0.001). However, there was no difference in overall life expectancy (p=0.770). Conclusion: A significant prevalence of AKI was found in patients with leukemia or lymphoma while they were hospitalized for BMT, resulting in significantly increased rates of in-hospital mortality. The presence of AKI during hospitalization was not associated with a subsequent reduction in life expectancy.

Introdução: As neoplasias hematológicas, incluindo linfomas e leucemias, podem ser tratadas com transplante autólogo ou halogênico de medula óssea. No entanto, essas abordagens podem aumentar o risco de infecção, sepse, doença do enxerto contra o hospedeiro e nefrotoxicidade, possivelmente resultando em lesão renal aguda (LRA). Objetivo: Avaliar LRA em pacientes com linfomas ou leucemia submetidos a transplante de medula óssea (TMO). Método: Estudo de coorte observacional retrospectivo de casos de um banco de dados de 256 pacientes (53,9% do sexo masculino) internados por TMO entre 2012 e 2014 em um hospital oncológico de São Paulo, Brasil. Destes, 79 prontuários foram selecionados aleatoriamente para análise. Dados demográficos, tempo de internação e morbidades associadas foram registrados. A LRA foi identificada de acordo com os critérios de Kidney Diseases Improving Global Outcomes (KDIGO). Resultados: Os diagnósticos mais frequentes da amostra de 79 casos foram linfoma não Hodgkin (30,4%), leucemia mieloide aguda (26,6%) e linfoma de Hodgkin (24,1%). A probabilidade de sobrevivência em 100 dias após o TMO foi de 81% e, em três anos após o TMO, foi de 61%. A mortalidade intra-hospitalar foi significativamente maior entre os pacientes que apresentaram LRA durante a internação (p<0,001). No entanto, não houve diferença na expectativa de vida geral (p=0,770). Conclusão: Neste estudo, observou-se prevalência significativa de LRA em pacientes com leucemia ou linfoma durante a internação por TMO, resultando em aumento significativo das taxas de mortalidade intra-hospitalar. A presença de LRA durante a hospitalização não se associou a uma subsequente redução da expectativa de vida

Introducción: Las neoplasias malignas hematológicas, incluidos los linfomas y las leucemias, pueden tratarse con trasplante autólogo o alogénico de médula ósea. Sin embargo, estos enfoques pueden aumentar el riesgo de infección, sepsis, enfermedad de injerto contra huésped y nefrotoxicidad, lo que posiblemente provoque lesión renal aguda (IRA). Objetivo: Evaluar el FRA en pacientes con linfomas o leucemias sometidos a trasplante de médula ósea (TMO). Método: Se realizó un estudio de cohorte observacional retrospectivo de casos de una base de datos de 256 pacientes (53,9% hombres) hospitalizados por TMO entre 2012 y 2014 en un hospital de cáncer en São Paulo, Brasil. De estos, 79 registros fueron seleccionados aleatoriamente para su análisis. Se registraron los datos demográficos, la duración de la hospitalización y las morbilidades asociadas. La IRA se identificó según los criterios de Kidney Diseases Improving Global Outcomes (KDIGO). Resultados: Los diagnósticos más frecuentes en la muestra de 79 casos fueron linfoma no Hodgkin (30,4%), leucemia mieloide aguda (26,6%) y linfoma de Hodgkin (24,1%). La probabilidad de supervivencia 100 días después del BMT fue del 81% y tres años después del BMT fue del 61%. La mortalidad hospitalaria fue significativamente mayor entre los pacientes que presentaron FRA durante la hospitalización (p<0,001). Sin embargo, no hubo diferencia en la esperanza de vida global (p=0,770). Conclusión: En este estudio, se observó una prevalencia significativa de LRA en pacientes con leucemia o linfoma mientras estaban hospitalizados por TMO, lo que resultó en un aumento significativo de las tasas de mortalidad hospitalaria. La presencia de FRA durante la hospitalización no se asoció con una reducción posterior de la esperanza de vida.

Marginal zone lymphoma of the dura - two case reports with long-term follow-up.

Primary MALT lymphoma arising at the dura is a rare circumstance with no categorical therapeutic plan in literature. There are few reports available with different treatment courses. Here, we report two cases with a long-term follow-up after the same pattern of management and review the literature.

Measurement of oral health quality of life among patients who underwent haematopoietic stem-cell transplantation.

Oral mucositis is a painful condition that occurs in patients who have undergone haematopoietic stem-cell transplantation (HSCT) and has a huge impact on their quality of life. The objective of this study was to examine the extent to which interleukin-6 (IL-6) and tumour necrosis factor alpha (TNF-α) are associated with oral health quality of life among patients who underwent HSCT. A. C. Camargo Cancer Center patients were evaluated over 20 months at 4 different time-points: a) at patient admission (M1); b) on the day of infusion of HSC (M2); c) 12 and 20 days after the first day of the conditioning regimen for autologous and allogeneic transplantation, respectively (M3); and d) 30 days after the first day of the conditioning regimen (M4). Mucositis clinical evaluations were performed using World Health Organization (WHO) criteria. Oral health quality of life was measured using the Oral Health Impact Profile short form (OHIP-14), Oral Mucositis Quality of Life (OMQoL) and Patient-Reported Oral Mucositis Symptom (PROMS) scales. Correlations between clinical data and quality of life scores were examined. STATA 11.0 was used to perform the statistical analyses (5% level of significance). Eighty-two patients participated in the study; 62.2% were male, 28.05% had multiple myeloma, and the mean age was 48.49 years (SD 13.76). Higher scores (worse quality of life) were observed as mucositis scores increased, but the results were not significant. The OMQoL had a high correlation with OHIP-14 (0.8377), but the correlation between the PROMS scale and the OHIP-14 was lower (0.6643). Higher concentrations of IL-6 and TNF-α were associated with worse quality of life, according to all indices (p < 0.05). Oral mucositis was associated with quality of life scores (p < 0.01).

Measurement of oral health quality of life among patients who underwent haematopoietic stem-cell transplantation

Abstract Oral mucositis is a painful condition that occurs in patients who have undergone haematopoietic stem-cell transplantation (HSCT) and has a huge impact on their quality of life. The objective of this study was to examine the extent to which interleukin-6 (IL-6) and tumour necrosis factor alpha (TNF-α) are associated with oral health quality of life among patients who underwent HSCT. A. C. Camargo Cancer Center patients were evaluated over 20 months at 4 different time-points: a) at patient admission (M1); b) on the day of infusion of HSC (M2); c) 12 and 20 days after the first day of the conditioning regimen for autologous and allogeneic transplantation, respectively (M3); and d) 30 days after the first day of the conditioning regimen (M4). Mucositis clinical evaluations were performed using World Health Organization (WHO) criteria. Oral health quality of life was measured using the Oral Health Impact Profile short form (OHIP-14), Oral Mucositis Quality of Life (OMQoL) and Patient-Reported Oral Mucositis Symptom (PROMS) scales. Correlations between clinical data and quality of life scores were examined. STATA 11.0 was used to perform the statistical analyses (5% level of significance). Eighty-two patients participated in the study; 62.2% were male, 28.05% had multiple myeloma, and the mean age was 48.49 years (SD 13.76). Higher scores (worse quality of life) were observed as mucositis scores increased, but the results were not significant. The OMQoL had a high correlation with OHIP-14 (0.8377), but the correlation between the PROMS scale and the OHIP-14 was lower (0.6643). Higher concentrations of IL-6 and TNF-α were associated with worse quality of life, according to all indices (p < 0.05). Oral mucositis was associated with quality of life scores (p < 0.01).

Mobilization of hematopoietic progenitor cells for autologous transportation: consensus recommendations.

Selected patients with certain hematological malignancies and solid tumors have the potential to achieve long-term survival with autologous hematopoietic progenitor cell transplant. The collection of these cells in peripheral blood avoids multiple bone marrow aspirations, results in faster engraftment and allows treatment of patients with infection, fibrosis, or bone marrow hypocellularity. However, for the procedure to be successful, it is essential to mobilize a sufficient number of progenitor cells from the bone marrow into the blood circulation. Therefore, a group of Brazilian experts met in order to develop recommendations for mobilization strategies adapted to the reality of the Brazilian national health system, which could help minimize the risk of failure, reduce toxicity and improve the allocation of financial resources.

Mobilization of hematopoietic progenitor cells for autologous transportation: consensus recommendations / Mobilização de células progenitoras hematopoéticas para transplante autólogo: recomendações de consenso

SUMMARY Selected patients with certain hematological malignancies and solid tumors have the potential to achieve long-term survival with autologous hematopoietic progenitor cell transplant. The collection of these cells in peripheral blood avoids multiple bone marrow aspirations, results in faster engraftment and allows treatment of patients with infection, fibrosis, or bone marrow hypocellularity. However, for the procedure to be successful, it is essential to mobilize a sufficient number of progenitor cells from the bone marrow into the blood circulation. Therefore, a group of Brazilian experts met in order to develop recommendations for mobilization strategies adapted to the reality of the Brazilian national health system, which could help minimize the risk of failure, reduce toxicity and improve the allocation of financial resources.

RESUMO Pacientes selecionados com certas neoplasias hematológicas e tumores sólidos têm o potencial de alcançar sobrevida de longo prazo com o transplante autólogo de células progenitoras hematopoéticas. A coleta dessas células no sangue periférico evita múltiplas aspirações de medula óssea, resulta em enxertia mais rápida, e permite o tratamento de pacientes com infiltração, fibrose ou hipocelularidade medular. Contudo, para o sucesso desse procedimento, é essencial mobilizar um número suficiente de células progenitoras da medula óssea para a circulação sanguínea. Por isso, um painel de especialistas brasileiros se reuniu com o objetivo de desenvolver recomendações para estratégias de mobilização adaptadas à realidade do sistema de saúde nacional, que pudessem contribuir para minimizar os riscos de falha, reduzir a toxicidade e melhorar a alocação de recursos financeiros.